Holger N. Lode, MD: Neuroblastoma Survival Update

2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

Holger N. Lode, MD, of the University of Greifswald, discusses the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-cell Ig-like receptor genotypes and Fc-receptor polymorphisms. (Abstract 111)

Advertisement

Advertisement



Advertisement

click me